Published in
Elsevier, European Journal of Cancer, (102), p. 40-48, 2018
DOI: 10.1016/j.ejca.2018.07.013
Links
Tools
Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04)
Journal article published in 2018 by
A. G. J. van Rossum,
M. Kok,
E. van Werkhoven,
M. Opdam,
I. A. M. Mandjes,
A. E. van Leeuwen – Stok,
H. van Tinteren 
,
A. L. T. Imholz,
J. E. A. Portielje ,
M. M. E. M. Bos,
A. van Bochove,
J. Wesseling,
E. J. Rutgers,
S. C. Linn,
H. M. Oosterkamp
,
A. L. T. Imholz,
J. E. A. Portielje ,
M. M. E. M. Bos,
A. van Bochove,
J. Wesseling,
E. J. Rutgers,
S. C. Linn,
H. M. Oosterkamp
This paper is made freely available by the publisher.
Full text: Download
Published version:
archiving forbidden
Data provided by 